ESC 2023 | ARREST Trial: Is It Necessary to Have Specialized Hospitals for Cardiac Arrest?

Researchers conducted a randomized study involving 827 patients who experienced out-of-hospital cardiac arrest without ST-segment elevation myocardial infarction, and then underwent percutaneous coronary intervention. In this group, 414 patients were transferred to a specialized cardiac arrest center (CAC), while 413 were taken to the geographically closest hospital (closest emergency department, CED).

ESC 2023

The primary endpoint (PEP) was all-cause mortality at 30 days. The average age of participants was 63 years, 31% of subjects were women, and both groups had similar characteristics.

At 30 days, there were no differences in the PEP between the two groups (63% in both groups; unadjusted relative risk of survival, 1.00; 95% confidence interval, 0.90-1.11; p=0.96).

In conclusion, the authors note that, for patients who experience cardiac arrest successfully reversed with CPR maneuvers, there were no differences between being transported to a specialized cardiac arrest center or a standard hospital.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Source: Presentado por Tiffany Patterson durante el Congreso ESC 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...